Drug Trial Radar · NCT00000885
Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320
Last checked: Nov 19, 2026Latest source record: Oct 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
440
Actual
Start
Not stated
Primary completion
Not stated
Study completion Jun 2003
Sponsor
- Sponsor type
- NIH
- First posted
- Aug 31, 2001
Design
- Study type
- Interventional
- Phase
- Phase 2
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Group A: To compare the time to confirmed virologic failure (2 consecutive plasma HIV-RNA concentrations of 500 copies/ml or more) between the treatment arms: abacavir (ABC) or placebo in combination with zidovudine (ZDV), lamivudine (3TC), and indinavir (IDV). To evaluate the safety and tolerability of these treatment arms. \[AS PER AMENDMENT 06/16/99: To compare the time to confirmed treatment failure, permanent discontinuation of treatment, or death between the treatment arms.\] \[AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable.\] Group B: To compare the proportion of patients who achieve plasma HIV-1 RNA concentrations below 500 copies/ml, as assessed by the standard Roche Amplicor assay at Week 16, or to compare the absolute changes in plasma HIV-1 RNA concentrations at Week 16 across the treatment arms: ABC or approved nucleoside analogs and nelfinavir (NFV) or placebo in combination with efavirenz (EFV) and adefovir dipivoxil. To compare the safety and tolerability of these treatment arms. Group C: To monitor plasma HIV-1 RNA trajectory over time and determine the time to a confirmed plasma HIV-1 RNA concentration above 2,000 copies/ml on 2 consecutive determinations for patients treated with ZDV or stavudine (d4T) plus 3TC and IDV. Group D: To evaluate plasma HIV-1 RNA responses at Weeks 16 and 48. To evaluate the safety and tolerability of the treatment arms: ABC, EFV, adefovir dipivoxil, and NFV. This study explores new treatment options for ACTG 320 enrollees (and, if needed, a limited number of non-ACTG 320 volunteers) who have been receiving ZDV (or d4T) plus 3TC and IDV and are currently exhibiting a range of virologic responses. By dividing the study into the corresponding, nonsequential cohorts (Groups A, B, C, D), different approaches to evaluating virologic success, i.e., undetectable plasma HIV-1 RNA levels, and virologic failure, i.e., plasma HIV-1 RNA levels of 500 copies/ml or more \[AS PER AMENDMENT 12/27/01: 200 copies/ml or more\], are explored while maintaining long-term follow-up of ACTG 320 patients. \[AS PER AMENDMENT 12/27/01: Groups B, C, and D completed follow-up on March 4, 1999. Therefore, only information pertinent to Group A is applicable. This study will examine the question of whether intensification of therapy can prolong the virologic benefit in individuals whose plasma HIV-1 RNA concentrations have been below the limits of assay detection on ZDV (or d4T) plus 3TC plus IDV.\]
Conditions
- HIV Infections
Interventions
Indinavir sulfateDrug
Abacavir sulfateDrug
Nelfinavir mesylateDrug
EfavirenzDrug
LevocarnitineDrug
Adefovir dipivoxilDrug
LamivudineDrug
StavudineDrug
ZidovudineDrug
DidanosineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
No primary outcomes listed.
Locations
53 sites in 2 countries. Site status is shown where the registry gives one.
Univ of Alabama at Birmingham
Birmingham, Alabama
Univ of Southern California / LA County USC Med Ctr
Los Angeles, California
Stanford at Kaiser / Kaiser Permanente Med Ctr
San Francisco, California
Santa Clara Valley Med Ctr / AIDS Community Rsch Consortium
San Jose, California
San Mateo AIDS Program / Stanford Univ
Stanford, California
Stanford Univ Med Ctr
Stanford, California
Harbor UCLA Med Ctr
Torrance, California
Univ of Colorado Health Sciences Ctr
Denver, Colorado
Georgetown Univ Hosp
Washington D.C., District of Columbia
Howard Univ
Washington D.C., District of Columbia
Univ of Miami School of Medicine
Miami, Florida
Emory Univ
Atlanta, Georgia
Queens Med Ctr
Honolulu, Hawaii
Univ of Hawaii
Honolulu, Hawaii
Northwestern Univ Med School
Chicago, Illinois
Cook County Hosp
Chicago, Illinois
Rush Presbyterian - Saint Luke's Med Ctr
Chicago, Illinois
Louis A Weiss Memorial Hosp
Chicago, Illinois
Indiana Univ Hosp
Indianapolis, Indiana
Division of Inf Diseases/ Indiana Univ Hosp
Indianapolis, Indiana
Methodist Hosp of Indiana / Life Care Clinic
Indianapolis, Indiana
Univ of Iowa Hosp and Clinic
Iowa City, Iowa
Tulane Univ School of Medicine
New Orleans, Louisiana
Johns Hopkins Hosp
Baltimore, Maryland
Harvard (Massachusetts Gen Hosp)
Boston, Massachusetts
Boston Med Ctr
Boston, Massachusetts
Beth Israel Deaconess - West Campus
Boston, Massachusetts
Beth Israel Deaconess Med Ctr
Boston, Massachusetts
Univ of Minnesota
Minneapolis, Minnesota
St Louis Regional Hosp / St Louis Regional Med Ctr
St Louis, Missouri
Univ of Nebraska Med Ctr
Omaha, Nebraska
SUNY / Erie County Med Ctr at Buffalo
Buffalo, New York
Beth Israel Med Ctr
New York, New York
Bellevue Hosp / New York Univ Med Ctr
New York, New York
Chelsea Ctr
New York, New York
Cornell Univ Med Ctr
New York, New York
St Vincent's Hosp / Mem Sloan-Kettering Cancer Ctr
New York, New York
Mount Sinai Med Ctr
New York, New York
Univ of Rochester Medical Center
Rochester, New York
Univ of North Carolina
Chapel Hill, North Carolina
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.